Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.075 USD | -3.15% | +7.50% | +2.38% |
Apr. 01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 26 | Transcript : Quince Therapeutics, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+2.38% | 47.97M | |
+3.84% | 43.43B | |
+47.81% | 41.69B | |
+9.76% | 41.31B | |
-10.92% | 27.14B | |
+9.10% | 25.28B | |
-24.76% | 18.47B | |
+29.38% | 12.59B | |
+0.94% | 12.33B | |
+8.26% | 11.03B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Cortexyme Says Trial Shows Atuzaginstat Slowed Cognitive Decline in Patients With Alzheimer's Disease, Porphyromonas Gingivalis Infection